Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
Comentado por Dra. Paloma Porto* O câncer de mama receptor hormonal positivo (HR+) e Her2 negativo
Dra. Paloma Porto
05/09/2023